DNTOX receives €1.4 million seed funding for non-animal testing of chemicals
The new capital will be used to set up the test laboratories in Düsseldorf, aim for GLP accreditation and launch the test battery on the market
The Life Science startup DNTOX receives seed funding of €1.4 million. The round is led by HTGF, with private investors Barbara Korte-Sturm and Nikolaus Sturm as well as Bool Capital and AQAL Capital also participating. The Düsseldorf-based company has developed a test system based on human cells that maps important processes in human brain development and thus enables the testing of chemicals without the need for animal experiments.
It is a legal requirement that substances that are harmful to the adult brain must also be tested for their effect on the developing brain. Testing evaluates the so-called developmental neurotoxicity (DNT). To date, these tests have been carried out primarily in a large number of animal experiments on rodents and are not only ethically questionable but also extremely time-consuming and costly. In addition, the results can only be transferred to humans to a limited extent due to species differences.
DNTOX’s system, consisting of a battery of individual tests combined with proprietary readout and evaluation algorithms, provides a suitable solution that enables cheaper, faster and ethically safe testing for customers in the chemical, pharmaceutical and cosmetic industries.
With the capital raised, the young company is building up the cell culture laboratories in Düsseldorf and is aiming for GLP accreditation in the near future. Thus positioned, the test system can be introduced to the market and rolled out.
"It is high time to establish meaningful and economically viable methods to replace animal testing. In our view, the DNTOX test battery is one such method and we are very confident that chemicals will no longer be tested in animals for their potential neurotoxicity in the future. In addition, we are excited by the enthusiasm and will of the entire DNTOX team to bring this method to market", Dr. Caroline Fichtner, Principal at HTGF.
"Experienced and highly respected scientists using their skills to solve a powerful problem through a product and even a company is rare. We are excited about the diverse DNTOX team and its impact on global health. We look forward to helping it succeed", Tom Schulz, co-founder and managing director of Aqal Capital GmbH.
Other news from the department business & finance
These products might interest you
CyBio FeliX by Analytik Jena
Automation of Cellular Assays
Flexible Pipetting Platform for Fully Automated Single to Multichannel Liquid Handling
RapidScan ST5-W Lateral Flow Assay Reader by Gold Standard Diagnostics Corp
LFD Assay Reader Validated for Multiple Food and Environmental Rapid Tests
Obtain quick and reliable results with an accurate, easy to use and highly flexible imaging platform
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
